Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival.

e20710 Background: Currently, prognostic markers associated with immunotherapy treatment outcomes in patients with metastatic NSCLC include PDL-1 expression, tumor mutational burden (TBM), and neutrophil to lymphocyte ratio (NLR). In this study we examine the influence of pretreatment changes in weight, BMI, and NLR in 237 patients treated with anti-PD-1/PDL-1 therapy (ICI) at our institution. Methods: This was a retrospective analysis of previously-treated stage IV NSCLC patients who received ICI. Pretreatment (≥ 6 weeks before starting therapy) values of weight, BMI, and NLR were compared to baseline values and NLR was analyzed as continuum and according to standard cutoffs of 3.5 and 5. The same variables were correlated with progression-free survival (PFS) and overall survival (OS) using the Log-Rank test. Results: 237 patients were analyzed: 45% were male, 73% were Caucasian, 72% were former smokers, and 25% were age ≥ 75 years. 148 patients had pretreatment NLR values. Of these, 32% had a ratio < 3.5 and 54% had ratio < 5. 34% had increased NLR at baseline, the majority of which (48/77) had a > 5% increase. 187 patients had pretreatment weight and BMI. Of these, 14% had a pretreatment BMI < 20. 71% had a negative change in BMI and 29% had a > 5% decrease in BMI. 65% had a negative change in weight and 26% had a > 5% decrease in weight. BMI decrease greater than 5% (p = 0.0039), negative weight change (p = 0.0371), and pretreatment NLR > 5 (p = 0.0136) were associated with shorter PFS. Change in NLR trended towards decreased PFS but was not statistically significant (p = 0.07) though only 77 of 237 patients had both values available. There was no statistical PFS difference between patients less than or ≥ 75 years old. Conclusions: The results suggest that decrease in pretreatment BMI and weight along with high baseline NLR are associated with significantly shorter PFS in NSCLC treated with anti-PD-1/PDL-1 therapy. If confirmed, these observations raise the possibility that specific treatment which reverses cancer associated weight loss might enhance effectiveness of immunotherapy.

Download Full-text

Evaluation of different MET genotypes as biomarkers for immunotherapy outcomes in NSCLC patients.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e21032 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e21032-e21032

Author(s):

Xuanzong Li ◽

Linlin Wang

Keyword(s):

Checkpoint Inhibitors ◽

Progression Free Survival ◽

Rank Test ◽

Wild Type ◽

Exact Test ◽

Entire Cohort ◽

Kaplan Meier ◽

Tumor Mutational Burden ◽

The Difference ◽

Nsclc Patients

e21032 Background: Previous studies suggested that MET exon 14 ( METex14) mutation regarding as a distinct subset was sensitive to MET-inhibitors, but poorly response to immunotherapy. Conversly, MET non-exon-14 (non-ex14) mutations including those undetermined functions and affecting the kinase or extracellular domains were found to be associated with the resistance to MET-inhibitors. However, therapeutic strategies for MET-non-ex14 mutant cancer are still largely unknown, and the relationship between MET-non-ex14 mutations and the efficacy of immune checkpoint inhibitors (ICIs) has never been reported. Using two public ICIs-treated cohorts, we aimed to assess the role of MET mutations including both METex14 and MET-non-ex14 mutations in NSCLC patients undergoing ICIs therapy. Methods: A total of 385 ICIs-treated NSCLC patients were enrolled to our study. MET mutations were defined as any nonsynonymous mutations, and we divided them into METex14 and MET-non-ex14 mutation subsets according to the mutated-position on MET. Kruskal-Wallis test was used to analyze the difference of tumor mutational burden (TMB) score, and the Fisher’s exact test was applied to compare the rates of durable clinical benefit (DCB). Log-rank test was used to analyze the differences between Kaplan-Meier survival curves. Results: In the entire cohort, we found that 17 patients (17/385, 4.4%) had MET mutations, most of which were pure METex14 mutations (10/17, 58.8%). The median TMB of patients in the entire NSCLC cohort was 6.89 mut/Mb. MET-non-ex14 mutant patients (7/385, 1.8%) possessed a significantly higher TMB than METex14-mutant (10/385, 2.6%) and MET wild-type (368/385, 95.6%) sub-cohorts, respectively (median TMB, 17.92 mut/Mb versus 4.17 mut/Mb, p = 0.008; 17.92 mut/Mb versus 6.96 mut/Mb, p = 0.01, respectively). DCB was more common in patients harbored MET-non-ex14 mutations than patients with METex14 mutations and MET wild-type (66.7% versus 14.3%, p = 0.103; 66.7% versus 29.9%, p = 0.075, respectively). We found that patients with MET-non-ex14 mutations had a numerically longer progression free survival (PFS) than those with METex14 mutations and MET wild-type (p = 0.169). Moreover, the PFS was significantly longer in MET-non-ex14-mutant subgroup than patients with METex14 mutations (median PFS, 9.1 versus 2.1 months, p = 0.025). Correspondingly, the overall survival (OS) was significantly longer in MET-non-ex14-mutant subgroup than their wild-type counterparts (median OS, not reached versus 11 months, p = 0.039). Additionally, patients with MET-non-ex14 mutations exhibited relatively better OS versus METex14-mutant patients (median OS, not reached versus 18 months, p = 0.175). Conclusions: MET-non-ex14 mutations were associated with higher TMB, improved DCB rate, and could act as a favorable prognostic biomarker in ICIs-treated NSCLC patients.

Download Full-text

Characterization of BCL-2 alternative proteins and outcome in patients with peripheral T-cell lymphoma (PTCL).

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e19531 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e19531-e19531

Author(s):

Mario L. Marques-Piubelli ◽

Luisa Maren Solis ◽

Luis Malpica ◽

Sushant Gouni ◽

Ranjit Nair ◽

...

Keyword(s):

Treatment Strategies ◽

Stage Iv ◽

Progression Free Survival ◽

Response To Therapy ◽

Rank Test ◽

Cell Transplant ◽

Functional Studies ◽

Tissue Biopsy ◽

Previously Treated

e19531 Background: The outcome of patients with PTCL, NOS is generally very poor, and the identification of biologically rational targets, which may translate into effective and non-toxic treatment strategies, is a high priority. The pro-survival BCL-2 family members BCL-2, BCL-XL (BCL2L1), BCL-W (BCL2L2), BCL2A1 and MCL-1 contribute to tumor maintenance, progression, and chemo-resistance across a range of cancers, but their contributions in PTCL, NOS are poorly understood. Methods: Patients with PTCL, NOS treated between 09/2000 and 09/2019 and with available tissue biopsy were included in the study. Diagnosis was retrospectively confirmed by two expert hematopathologists. BCL-2, BCL-XL, BCL-W, BCL2A1 and MCL-1 expression was assessed by immunohistochemistry (IHC), and the percentage of positive tumor cells assessed by standard microscopy. The 2014 Lugano Classification was used to define response to therapy. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and were compared using log-rank test between patient groups. Results: Twenty-seven patients were included in the study: 67% were male, 52% ≥ 65 year old, and 48% had stage IV disease; 59% were previously treated and 41% received > 2 lines of therapy, including stem cell transplant (SCT) in 19%. The median expression of BCL-2, BCL-XL, BCL-W, BCL2A1 and MCL-1 by IHC was: 30% (range: 0-100%), 10% (range: 0-90%), 100% (range: 40-100%), 20% (range: 0-90%), and 70% (range: 1-100%), respectively. BCL-2A1 was significantly higher in previously treated patients (35% vs 5%, p = 0.02), and in those who had previously received > 2 lines of therapy (40% vs 5%, p = 0.02). Twenty-four (89%) patients were treated after tissue biopsy, 17 (63%) with chemotherapy, 7 (26%) with biological therapy, and 6 (22%) received subsequent SCT. Five (24%) patients achieved complete remission (CR); only BCL-W associated with response, a higher expression (quartiles 3 and 4) being observed among patients not achieving CR (median 100% vs 90%, p = 0.07). After a median follow-up of 28 months (95% CI, 14-42 months), 22 (81%) patients progressed or died, and median PFS was 4 months (95% CI, 2-6 months); only BCL-W associated with PFS, a shorter median PFS being observed for patients with higher expression (3 months vs 7 months, p = 0.001). At most recent follow-up, 17 (63%) patients died, and median OS was 6 months (95% CI, 1-12 months). only BCL-W associated with OS, a shorter median OS being observed for patients with higher expression (4 months vs not reached, p = 0.004). Conclusions: High expression of BCL-W associates with significantly worse outcome in patients with PTCL, NOS. While clinical trials investigating the safety and efficacy of BCL-2 inhibition in PTCL, NOS are ongoing, these results suggest that concomitant BCL-W inhibition may be beneficial, and functional studies aimed at confirming these findings are highly needed.

Download Full-text

Two year progression free survival in stage IV NSCLC patients treated with pemetrexed continuation maintenance.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e20654 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e20654-e20654

Author(s):

Jason Nathaniel Macklis ◽

Fatima Saleem ◽

Fatema Mohammed Esmail ◽

Sanjib Basu ◽

Mary J. Fidler ◽

...

Keyword(s):

Stage Iv ◽

Progression Free Survival ◽

Free Survival ◽

Continuation Maintenance ◽

Nsclc Patients

Download Full-text

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G

Cancers ◽

10.3390/cancers12071715 ◽

2020 ◽

Vol 12 (7) ◽

pp. 1715

Author(s):

Hiroya Taniguchi ◽

Takeharu Yamanaka ◽

Daisuke Sakai ◽

Kei Muro ◽

Kentaro Yamazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Progression Free Survival ◽

Phase Iii ◽

Rank Test ◽

Clinical Trial Registration ◽

Cox Models ◽

Exon 2 ◽

Free Survival ◽

Previously Treated

Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received bevacizumab either prior to panitumumab or cetuximab monotherapy (ASPECCT) or in combination with irinotecan (WJOG6510G) was included. Multivariate Cox models were created, including the treatment arms as covariates together with patient, disease and treatment characteristics. Results: We included 185 and 189 patients in the panitumumab and cetuximab arms, respectively. The median overall survival was 12.8 and 10.1 months [p = 0.0031; log-rank test, stratified by trial; hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.58–0.90], and the median progression-free survival was 4.7 and 4.1 months, in the panitumumab and cetuximab arms, respectively (p = 0.0207; HR, 0.79; 95% CI, 0.64–0.97). The treatment regimen was an independent prognostic factor of overall survival (adjusted HR, 0.69; 95% CI, 0.54–0.87; p = 0.0013). Conclusions: Panitumumab significantly prolonged the overall survival and progression-free survival, when compared with cetuximab in the cohort that previously received bevacizumab in the included studies. Clinical Trial Registration: ASPECCT trial registered with ClinicalTrials.gov (NCT01001377) and WJOG6510G trial registered with UMIN-CTR (UMIN000006643).

Download Full-text

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

Frontiers in Oncology ◽

10.3389/fonc.2021.671228 ◽

2021 ◽

Vol 11 ◽

Author(s):

Ya Chen ◽

Zhengyu Yang ◽

Yanan Wang ◽

Minjuan Hu ◽

Bo Zhang ◽

...

Keyword(s):

Multivariate Analysis ◽

Prognostic Factors ◽

Prognostic Factor ◽

Egfr Mutation ◽

Combined Therapy ◽

Progression Free Survival ◽

Free Survival ◽

Median Progression Free Survival ◽

Previously Treated ◽

Nsclc Patients

ObjectivesMore and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunotherapy is still a controversy for NSCLC patients with EGFR mutation.MethodIn this retrospective analysis, we compared the clinical efficacy of pembrolizumab monotherapy (PM), pembrolizumab combined with chemotherapy (P+C) and pembrolizumab combined with anlotinib (P+A) in NSCLC patients with EGFR mutation who had failed on EGFR-TKI and platinum-based chemotherapy.ResultEighty-six patients were included in this study. The overall median progression free survival (PFS) was 3.24 months. Multivariate analysis suggested that EGFRL858R and combined therapy were positive prognostic factors of PFS. The overall median OS was 12.28 months. Multivariate analysis found that high PD-L1 expression (≥50%) and combined therapy seemed to be positive prognostic factors of OS. Among the population, 32 patients received PM, 26 patients received P+C and 28 patients received P+A. Up to Jan 30, 2021, the median progression-free survival was 1.5 months in the PM group, 4.30 months in the P+C group and 3.24 months in the P+A group. The median OS were 7.41, 14.92 and 15.97 months, respectively. The ORR were 3.1%, 23.1% and 21.4%.ConclusionThe addition of chemotherapy or antiangiogenic therapy to pembrolizumab resulted in significantly longer PFS, OS and ORR than pembrolizumab alone in our study. EGFRL858R might be a positive prognostic factor of PFS and high PD-L1 expression might be a positive prognostic factor of OS.

Download Full-text

Number of cycles of chemotherapy in patients with advanced non-small cell lung caner: Efficacy and relationship with histology.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e18125 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e18125-e18125

Author(s):

Eduardo Richardet ◽

Martin Eduardo Richardet ◽

Nicolas Castagneris ◽

Matias Nicolas Cortes ◽

Perelli Laura ◽

...

Keyword(s):

Overall Survival ◽

Stage Iv ◽

Progression Free Survival ◽

Rank Test ◽

Test Results ◽

First Line ◽

Free Survival ◽

Log Rank Test ◽

Kaplan Meier ◽

Number Of Cycles

e18125 Background: Platinum based regimens are standard first-line treatment in patients with advanced non mall cell lung cancer. We intend to evaluate their effectiveness according to the number of cycles administered, and investigate whether histology is a predictor of benefit from a greater number of infusions. Methods: 124 patients with stage IV NSCLC were evaluated retrospectively. They were divided according to whether they made 4 or 6 cycles of chemotherapy. The schemes used were: Cisplatin / Gemcitabine and Carboplatin / Paclitaxel, at standard doses. We studied the efficacy in both groups according to the most common histologies (adenocarcinoma and squamous cell carcinoma). PFS (progression-free survival) and OS (overall survival) were calculated by the Kaplan-Meier curves and compared by the Log Rank Test. Results: Those who underwent 4 cycles had a PFS of 7.77 months and OS of 12.2 months vs. 8.64 and 10.8 months those who received 6 cycles (p = 0.47, p = 0.76). Within the subgroup with squamous histology (n = 43), PFS and OS were 7.38 and 13.38 months respectively in the group that received 4 cycles vs. 7.97 and 9.76 months in those receiving 6 (p = 0.70, p = 0.32 ). Within adenocarcinoma histology (n = 81), those who received 4 cycle, has a PFS of 8.17 months and they lived 11.56 month, vs 8.96 and 10.79 months for those receiving 6 cycles (p = 0.29, p = 0.88) Conclusions: In our population, a greater number of cycles showed no advantages in terms of progression-free survival or overall survival. Histology is not a predictive factor for deciding how many chemotherapy cycles administer.

Download Full-text

Phase (Ph) I study of pazopanib (P) in combination with vinorelbine (V) in patients with metastatic non-small cell lung cancer (mNSCLC) and breast cancer (mBC).

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e13568 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e13568-e13568

Author(s):

Ryan D. Gentzler ◽

Virginia G. Kaklamani ◽

Rebekah Worden ◽

Therese Zumdahl ◽

Hala D Simm ◽

...

Keyword(s):

Kinase Inhibitor ◽

Stage Iv ◽

Progression Free Survival ◽

Response Assessment ◽

Maximum Tolerated Dose ◽

Vegf Inhibitors ◽

Free Survival ◽

Previously Treated ◽

Dose Levels ◽

Clinical Trial Information

e13568 Background: V is an established treatment for mNSCLC and mBC, but combination 2nd line chemotherapy has not shown clear benefit for either disease. The anti-VEGF agent bevacizumab improves response rate and progression free survival (PFS) for mNSCLC and mBC. P is a tyrosine kinase inhibitor targeting the VEGF receptors. We hypothesize that because CYP3A4 is inhibited by P and responsible for metabolism of V, there may be synergy between P + V. This is a ph I study testing the combination of P + V in previously treated pts with mNSCLC and mBC. Methods: Pts with Stage IIIB/IV NSCLC or Stage IV mBC with ≤ 2 (lung) or ≤ 3 (breast) prior chemotherapies, no prior VEGF inhibitors, and PS 0-2 were treated with P + V. The objective was to determine the maximum tolerated dose (MTD) of P + V. Dose escalations followed a standard 3+3 design. After 6 pts, the protocol was amended to add an intermittent dosing cohort (2a) to improve tolerability. Response assessment (RA) occurred q 42 days (d) while on study. Pts had weekly toxicity assessments, and PK data was collected on d 1-2 of the first 2 cycles. Results: Eight pts (7 mNSCLC, 1 mBC) were enrolled in 3 of 9 planned cohorts. Pts received a median of 2 cycles. All pts experienced at least 1 grade (gr) 3/4 toxicity. Six dose-limiting toxicities occurred in 4 pts in cohort 2/2a. Five severe adverse events were reported in 4 pts and included thrombocytopenia, neutropenia, abdominal (abd) pain, pneumonia, and hepatotoxicity. Gr 3/4 toxicities were: neutropenia (6), fatigue (2), thrombocytopenia (1), hyperbilirubinemia (1), transaminitis (1), hypertension (1), abd pain (1), and pneumonia (1). 1 pt refused treatment after 1 cycle and had no RA. 5 of 8 pts expired due to progressive disease. No partial responses were noted. Median PFS was 66 d (95% CI 35 to 384 d). Conclusions: Combination of P + V in pre-treated mNSCLC and mBC results in high rates of gr 3/4 toxicities at all dose levels. The trial was suspended due to significant drug-drug interactions before the MTD could be determined. No further study of P in combination with V is warranted in either pt population. Clinical trial information: NCT01060514. [Table: see text]

Download Full-text

Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN).

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.8059 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 8059-8059

Author(s):

Benjamin Besse ◽

Sylvestre Le Moulec ◽

Hélène Senellart ◽

Julien Mazieres ◽

Fabrice Barlesi ◽

...

Keyword(s):

Brain Mri ◽

Stage Iv ◽

Progression Free Survival ◽

Free Survival ◽

Grade 3 ◽

Nsclc Patients ◽

Brain Hemorrhages ◽

Unacceptable Toxicity ◽

Line Chemotherapy

8059 Background: The non-comparative BRAIN study (NCT00800202) is the first trial to evaluate efficacy/acceptable safety of B in pts with ns-NSCLC and untreated BM. We report final efficacy/safety results. Methods: Eligible pts (stage IV ns-NSCLC; PS 0–1; untreated, asymptomatic BM ineligible for surgery/radiosurgery) received until unacceptable toxicity/disease progression: 1st-line B ≤6 cycles (15mg/kg q3w) plus carboplatin (AUC 6 q3w) and paclitaxel (200mg/m2 q3w; B+CP; n=67); or 2nd-line B plus E (150mg/day; B+E; n=24). Primary endpoint is 6-month progression-free survival (PFS). Six-weekly assessments included mandatory brain MRI. The trial could be halted if there were >3 (B+CP) or >2 (B+E) brain hemorrhages (ICH). Results: Baseline (BL) characteristics are reported. With a median follow-up of 16.3 (B+CP) and 11.8 months (B+E), efficacy data are summarized. Adverse events (AE) were comparable with those in previous trials of B. Only 1 grade ≥3 bleeding AE (grade 3, extracranial site; B+E) and only one ICH event (grade 1, resolved; B+CP) occurred. Most frequent cause for B withdrawal was progression: intracranial only in 20.9% (B+CP) and 16% (B+E); extracranial only in 50.7% (B+CP) and 54.2 % (B+E). Conclusions: The finalBRAIN results demonstrate promising efficacy and acceptable safety of B with 1st-line chemotherapy or 2nd-line E in ns-NSCLC pts with asymptomatic untreated BM. Clinical trial information: NCT00800202. [Table: see text]

Download Full-text

Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.1021 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. 1021-1021 ◽

Cited By ~ 1

Author(s):

Yao Wong ◽

Akshara Singareeka Raghavendra ◽

Christos Hatzis ◽

Javier Perez Irizarry ◽

Teresita Vega ◽

...

Keyword(s):

Overall Survival ◽

Targeted Therapies ◽

De Novo ◽

Stage Iv ◽

Progression Free Survival ◽

Rank Test ◽

Her2 Positive ◽

Free Survival ◽

Log Rank Test ◽

Her 2

1021 Background: An increasing number of metastatic HER2 positive cancers represent de novo stage IV disease as fewer early stage patients relapse. We hypothesize that a subset of these has long progression free survival (PFS) after initial combined modality HER2-targeted therapies. Methods: 483 patients with de novo stage IV HER2 positive breast cancer diagnosed between 1998-2015 were identified through the medical records at Yale and MD Anderson Cancer Centers, respectively. Treatment, clinical variables and survival were extracted and compared between those who achieved “no evidence of disease” (NED) status with initial therapy and those who did not. Results: All patients received trastuzumab and 94 (20%) also received pertuzumab as first line therapy.The median OS was 5.5 years (95% Cl: 4.8-6.2); OS rates at 5 and 10 years were 54% (95% CI: 48%-60.4%) and 18% (95% Cl: 11.4%-28.3%), respectively and PFS were 41% (95% CI: 35%-48%) and 41% (95% CI: 35%-48%). Sixty-three patients (13.0%; 95% CI: 10.2% -16.4%) achieved NED. The PFS and OS at 5 and 10 years were the same 100% and 98% (95% CI: 94.6%-100%), respectively. For patients with no-NED (n = 420), the median OS was 4.7 years (95% Cl: 4.2-5.3), the PFS and OS rates at 5 and 10 years were 12% (95% CI: 4.5%-30.4%) and 0% and 45% (95% CI: 38.4%-52.0%) and 4% (95% CI: 1.3%-13.2%), respectively. NED patients had significantly longer progression free survival (log-rank test p≤0.001) and overall survival (log-rank test p≤0.001), more frequently had single organ site metastasis (76% vs 57%, p = 0.005), and more frequently had surgery for primary tumor (59% vs. 25%, p ≤0.001) than no-NED patients, but there was no significant difference in age, grade, race, year of diagnosis, ER status, treatment distribution, or radiation between the groups. Conclusions: About 13% of de novo, stage IV, HER-2 positive MBC patients achieved NED with HER-2 targeted therapies, all of these patients were progression free at 5 years and overall survival at 10-years was 98% compared to 4% among those with no-NED in our data sets. These results suggest that aggressive multimodality therapy of newly diagnosed stage IV HER2 positive cancers to render them NED may be warranted.

Download Full-text